Suven Life Sciences Quarterly Results for Trading Insights
In Mar 2026, Suven Life Sciences (SUVEN) reported revenue ₹8 Cr and net profit ₹-46 Cr — revenue +166.7% YoY. View Suven Life Sciences yearly highs lows for the annual high/low range and current price position.
SUVEN Quarterly Results — Revenue, Profit & EPS Highlights
Suven Life Sciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit SUVEN screener.
- Revenue of ₹8 Cr in Mar 2026 (-27.3% vs Jun 2026, +166.7% vs Mar 2025)
- Net Profit of ₹-46 Cr in Mar 2026 (+64.1% vs Jun 2026, -4.5% vs Mar 2025)
- EBITDA of ₹-44 Cr in Mar 2026 (+64.8% vs Jun 2026)
- Operating Margin of -3331.0% in Mar 2026 (+380.0pp vs Jun 2026)
- Earnings Per Share of ₹-2.02 in Mar 2026 (+58.3% vs Jun 2026)
Suven Life Sciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SUVEN quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 8 | 11 | 5 | 3 | 3 | -27.3% | 166.7% |
| Net Profit (₹ Cr) | -46 | -128 | -77 | -44 | -52 | - | - |
| EBITDA (₹ Cr) | -44 | -125 | -76 | -43 | -50 | - | - |
| EPS (₹) | -2.02 | -4.84 | -3.48 | -2.02 | -2.36 | - | - |
| Operating Margin (%) | -3331.0% | -3711.0% | -8671.0% | -2981.0% | -2714.0% | - | - |
SUVEN Share Price Trend — 1-Year Movement Across Quarterly Results
Suven Life Sciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse SUVEN FII DII holdings to track promoter, FII and institutional holdings.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SUVEN vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Suven Life Sciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
|
Cipla
Mar 2026 |
₹109,705.39 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
All amounts in ₹ Crores